Welcome to our dedicated page for Spero Therapeuti news (Ticker: SPRO), a resource for investors and traders seeking the latest updates and insights on Spero Therapeuti stock.
Spero Therapeutics, Inc. develops clinical-stage treatments for rare diseases and diseases with high unmet need, with news centered on anti-infective programs for multi-drug resistant bacterial infections. Updates frequently cover tebipenem HBr, an investigational oral carbapenem antibiotic for complicated urinary tract infections, including pyelonephritis, and its licensed development and commercialization relationship with GSK outside certain Asian territories.
Company announcements also report quarterly and annual operating results, business updates, clinical data presentations, FDA submission activity, portfolio-expansion efforts, cash runway commentary, and equity-compensation grants under Nasdaq rules.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Spero Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright BioConnect Investor Conference on May 2, 2023. Management will present from 10:30 AM to 11:00 AM ET and is available for one-on-one meetings. Key products include SPR720, targeting non-tuberculous mycobacterial infections, and Tebipenem HBr, an investigational drug for complicated urinary tract infections (cUTI). Spero is also developing SPR206, an IV-administered candidate for multi-drug resistant Gram-negative infections. Investors can access the webcast through the Spero website after the event. The company focuses on addressing rare diseases and multi-drug resistant bacterial infections with promising therapies.